Allergic Rhinitis Drugs Market - By Disease (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), By Treatment (Antihistamines) By Drug, By Route of Administration, By Distribution Channel & Forecast, 2023-2032

Allergic Rhinitis Drugs Market Size

Allergic Rhinitis Drugs Market size was recorded at over USD 12 billion in 2022. Driven by consistent innovations in allergic rhinitis drugs, the industry is estimated to grow at more than 2.5% CAGR from 2023 to 2032.
 

The increasing prevalence of allergic rhinitis is expected to fuel market growth. Several epidemiological studies have shown that the disease burden caused by allergies has significantly increased in the past few years. Moreover, air quality deterioration in developed nations due to cumulative industrial practices has escalated the number of allergic rhinitis cases, which is speculated to bolster product penetration.
 

Furthermore, technological advancements in the field of allergy diagnosis and treatment are also forecast to positively influence business dynamics. The considerable surge in deploying technologically advanced methods, tools, and mechanisms by authorities and organizations globally has uplifted product adoption.
 

Side effects associated with allergic rhinitis treatments are a major factor restraining market growth. The most frequent side effects of treating allergic rhinitis are nosebleeds, excruciating migraines, eye and nose discomfort, urinary flow in males, and boost blood pressure in hypertensive patients. Altogether, the growing practice of self-medication without a doctor's prescription leads to difficulties. Nonetheless, mounting healthcare spending and the availability of highly potent drugs are likely to aid market players in overcoming this issue.
 

Allergic Rhinitis Drugs Market Analysis

Based on disease, the industry is split into seasonal allergic rhinitis, occupational allergic rhinitis, and perennial allergic rhinitis. The seasonal allergic rhinitis segment accounted for more than 42% of the allergic rhinitis drugs market share in 2022 and is further slated to witness robust growth in the coming years. The rise in breathing-related illnesses caused by outdoor allergens including weed and grass pollen is proliferating product uptake. As per the Asthma and Allergy Foundation of America, grass pollen affects around 10 to 30% of children and adults in the United States.
 

The allergic rhinitis drugs market is categorized in terms of drug into prescription and OTC. The prescription segment is speculated to account for a valuation of over USD 8.5 billion by 2032. The strong inclination of allergic patients experiencing a runny nose, itchy eyes, postnasal drip, and other symptoms toward prescription drugs is primarily accelerating segment share. The segment growth is also driven by the inclusion of a wide range of allergic drugs from several categories, including corticosteroids, antihistamines, and leukotriene receptor antagonists, among others, under the prescribed drug segment.
 

With respect to treatment, the allergic rhinitis drugs market is divided into antihistamines, corticosteroids, immunotherapy, decongestants, and others. The immunotherapy segment is poised to depict over 3% CAGR from 2023 to 2032. By using this technique, the body's immune system builds up an immunity to tolerate allergens and doesn't react to active allergens. As a result of its effectiveness on SAR patients, immunotherapy is considered the only disease-modifying therapy for allergic rhinitis. In addition, providers increase allergens in every shot, escalating immunity in the body.
 

Based on the route of administration, the industry is classified into oral, intraocular, nasal, and intravenous. The allergic rhinitis drugs market size from the oral segment is anticipated to garner more than USD 6.5 billion in revenue by 2032. The clinical advantages associated with the oral route of administration, such as its high level of convenience, low cost, and non-invasive approach, are encouraging segment uptake. Tablets, capsules, and solutions, among other formulations, are used to administer the oral dose.
 

In terms of distribution channel, the allergic rhinitis drugs market is separated into hospital pharmacies, retail pharmacies, and online channel. The online channel segment valuation is foreseen to reach over USD 4 billion by 2032. The rising use of online portals and e-commerce platforms for ordering and delivering prescription drugs at the convenience of patients is set to foster segment growth. Moreover, the availability of swift service, beneficial discounts & offers from various manufacturers, and the strong preference of elderly patients are driving the segment growth.
 

In the regional context, the allergic rhinitis drugs market is segmented into Europe, Asia Pacific, North America, the Middle East & Africa, and Latin America. The North America market registered more than 37% revenue share in 2022. Soaring technological developments in treatment methods such as corticosteroid drugs are fueling business outlook. For instance, in March 2022, US FDA approved Rx-to-OTC for Nasonex by Perrigo. Moreover, the positive focus of industry players on OTC product portfolio and rising healthcare expenditures are accelerating regional market expansion.
 

Allergic Rhinitis Drugs Market Share

• Merck & Co.
• GlaxoSmithKline PLC
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Unichem Laboratories
• Stallergenes Greer
• Sanofi S.A.
• Alcon (Novartis AG)
• Johnson & Johnson
• Meda AB
• Mylan NV
• Allergy Therapeutics PLC
• ALK-Abelló A/S
• Glenmark Pharmaceuticals Ltd
• Bayer AG
• Dr. Reddy’s Laboratories
• Adamis Pharmaceuticals
• Sun Pharmaceuticals

are key participants involved in the market. These firms focus on thorough R&D programs to expand their product portfolio and propel their market position.
 

Impact of COVID-19 Pandamic

The recent outbreak of COVID-19 had a negative impact on the allergic rhinitis drugs industry as a result of dynamic trends in demand, supply shortages, panic buying & stocking, regulation changes, and R&D process changes that impacted the market revenue. However, recently, the market observed a rapid recovery in line with new strategies undertaken by government agencies to manage AR patient burden as well as COVID-19 cases. For instance, the European Academy of Allergy and Clinical Immunology (EAACI), along with the ARIA-MASK study group, suggested the use of intranasal steroids for the treatment of allergic rhinitis, which has been lucrative for business growth.
 

The allergic rhinitis drugs market report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Disease

• Seasonal Allergic Rhinitis
• Perennial Allergic Rhinitis
• Occupational Allergic Rhinitis

By Treatment

• Antihistamines
• Immunotherapy
  • SCIT
  • SLIT
• Corticosteroids
• Decongestants
• Others

By Drug

• Prescription
• OTC

By Route of Administration

• Oral
• Nasal
• Intraocular
• Intravenous

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Channel

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • MEA